Navigation Links
EntreMed ENMD-2076 Phase 1 Data to Be Presented at ASCO Annual Meeting
Date:5/15/2009

ENMD-2076 Clinical Program Adds Leukemia Clinical Study and Orphan Drug Designation

ROCKVILLE, Md., May 15 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer today announced presentations for three of its clinical-stage drug candidates at the American Society of Clinical Oncology (ASCO) Annual Meeting to be held May 29 - June 2, 2009 in Orlando, Florida. Presentations include both poster and discussion sessions and are listed below.

  • Poster Session: Friday, May 29, 2009 - 2:00 p.m. - 6:00 p.m. Abstract No.: 3520, "An open-label, dose escalation, safety, and pharmacokinetic study of ENMD-2076 administered orally to patients with advanced cancer."
    • Discussion Session: Friday, May 29, 2009 - 5:00 p.m. - 5:15 p.m. "Angiogenesis Inhibitors: New Agents and New Combinations," Level 4, Valencia Room, W415D.
  • Poster Session: Saturday, May 30, 2009 - 8:00 a.m. - 12:00 p.m. Abstract No.: 3562, "A single center, open-label, dose escalation, safety, and pharmacokinetic study of ENMD-1198 administered orally to patients with advanced cancer."
  • Poster Session: Sunday, May 31, 2009 - 2:00 p.m. - 6:00 p.m. Abstract No: 5577, "Phase 2 study of MKC-1 in patients with metastatic or resistant epithelial ovarian cancer or advanced endometrial cancer."

(Logo: http://www.newscom.com/cgi-bin/prnh/20010620/ENMDLOGO )

The Company has furth
'/>"/>

SOURCE EntreMed, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. EntreMed Initiates ENMD-2076 Clinical Trial in Multiple Myeloma
2. EntreMed to Present at the New York Society of Security Analysts Industry Conference
3. EntreMeds MKC-1 Meets Primary Efficacy Endpoint in Non-Small Cell Lung Cancer Clinical Trial
4. EntreMed Reports Third Quarter 2008 Financial Results
5. EntreMeds ENMD-2076 Demonstrates Tumor Regression in Human Colon Cancer Model
6. EntreMed to Present at BioPartnering Europe Conference
7. EntreMed Announces Stock Listing Transfer to Nasdaq Capital Market
8. EntreMed Reports Second Quarter 2008 Financial Results
9. EntreMed Appoints Thomas H. Bliss as Senior Vice President of Corporate and Business Development
10. Dana-Farber Cancer Institute Commences Phase 1 Trial With EntreMeds Selective Kinase Inhibitor
11. EntreMed Will Not Seek Shareholder Approval for Reverse Stock Split at Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... In preparation for VARTECH 2014, 2FA, Inc., ... focused on authentication and SSO announced today that their ... generate a OTP through the presentation of an RFID ... RFID authentication, 2FA,s solutions have leveraged the existence of ... RFID authentication is broadly deployed in healthcare and other ...
(Date:9/15/2014)... Sept. 15, 2014   Global Science & ... scientific products and services for satellite and weather ... for Integrated Services (OASIS) from the General Services ... selected to provide the government best-value solutions for ... (SB) category in Pool 4. The OASIS SB ...
(Date:9/15/2014)... a patient has sepsis, a life-threatening condition in which ... often too fast for antibiotics to help. A new ... a team at Harvard,s Wyss Institute for Biologically Inspired ... , "Even with the best current treatments, sepsis ... 30 percent of the time," said Mike Super, Ph.D., ...
(Date:9/15/2014)...  iVinci Health LLC, the company behind the healthcare ... branded as VisitPay®, has successfully closed $5 million in ... a new extension to VisitPay® – an online Payment ... way for patients to manage their medical bills and ... their families. The new round of funding, ...
Breaking Biology Technology:2FA, Inc. Announces RFID-based One-Time Password (OTP) Authentication 2Global Science & Technology, Inc. Awarded GSA OASIS Small Business Contract 2Global Science & Technology, Inc. Awarded GSA OASIS Small Business Contract 3Blood-cleansing biospleen device developed for sepsis therapy 2Blood-cleansing biospleen device developed for sepsis therapy 3Blood-cleansing biospleen device developed for sepsis therapy 4iVinci Health Raises $5M to Fuel National Expansion, Announces Launch of Personal Finance Portal for Healthcare 2iVinci Health Raises $5M to Fuel National Expansion, Announces Launch of Personal Finance Portal for Healthcare 3
... FRANCISCO, Calif., Nov. 1, 2010 diaDexus, Inc. (OTC ... focused on the development and commercialization of patent-protected ... cardiovascular disease, today announced that the company, formerly known ... Board under the ticker symbol (VXGN), has been renamed ...
... Nov. 1, 2010 Amgen (Nasdaq: AMGN ) ... Ph.D., will urge members of a U.S. Food and Drug ... to establish approval standards that ensure patient safety and follow ... policy will follow," Dr. Miletich said.  "Amgen believes biosimilars have ...
... ... ... var shortURL = ""; BitlyCB.alertResponse = function(data) ... first one. for (var r in data.results) { first_result = data.results[r]; break; } for (var key in first_result) { ...
Cached Biology Technology:diaDexus Announces Name Change From VaxGen 2diaDexus Announces Name Change From VaxGen 3Amgen to Provide Testimony at FDA Hearing on Biosimilars 2Amgen to Provide Testimony at FDA Hearing on Biosimilars 3Amgen to Provide Testimony at FDA Hearing on Biosimilars 4NEURO-BIOTECH CORPORATION: Updates and latest developments 2NEURO-BIOTECH CORPORATION: Updates and latest developments 3NEURO-BIOTECH CORPORATION: Updates and latest developments 4NEURO-BIOTECH CORPORATION: Updates and latest developments 5NEURO-BIOTECH CORPORATION: Updates and latest developments 6NEURO-BIOTECH CORPORATION: Updates and latest developments 7NEURO-BIOTECH CORPORATION: Updates and latest developments 8NEURO-BIOTECH CORPORATION: Updates and latest developments 9
(Date:9/15/2014)... Mass. (September 15, 2014) The so-called central ... makes proteinhas long provided a simplified explanation for ... living organisms. , In reality, of course, ... schema first articulated nearly 60 years ago by ... double-helix structure. For one, there are multiple types ...
(Date:9/15/2014)... both plants and animals alike. , Understanding just how ... to the design of better drugs for diabetes patients ... vegetables farmers are able to grow. Stanford University researchers ... cell by piecing together proteins slightly wider than the ... determine the size, shape and orientation of one of ...
(Date:9/15/2014)... will allow us to better understand how the ... scenarios and provide the type of environmental data ... and siting of protected areas," said Paula Whitfield, ... Coastal Ocean Science (NCCOS) and lead author of ... within the temperate-tropical transition zone, where historically, both ...
Breaking Biology News(10 mins):Scientists discover RNA modifications in some unexpected places 2X-rays unlock a protein's SWEET side 2X-rays unlock a protein's SWEET side 3Study finds warming Atlantic temperatures could increase range of invasive species 2
... D.C., November 21, 2010 -- For centuries, hunters have imitated ... carving wooden bird calls. Now a team of physicists at ... characteristics of real bird song with a simple physical model ... know if you [could] build a simple device, which has ...
... baby,s first blurted "bowl!," for the word "ball" to the ... vocalizations is one of humankind,s most remarkable attributes -- and ... Not so for people who are afflicted with ... stigma of affected speech. Nor so for engineering professor Michael ...
... , Researchers in the United States have developed a ... from a patient,s own bone marrow. The research, published ... suffering from abnormally developed bladders, but also represents another ... research, led by Dr Arun Sharma and Earl Cheng ...
Cached Biology News:Simple rubber device mimics complex bird songs 2Air flows in mechanical device reveal secrets of speech pathology 2New study into bladder regeneration heralds organ replacement treatment 2
Request Info...
...
... High Resolution - Efficiently ... 50 to 1000 bp. ... sizing PCR fragments, small ... restriction enzyme digestion, and ...
... ZMD.358. Immunogen: Synthetic peptide ... of human mouse and rat ... human and mouse LRP5 proteins. ... controls: mouse LRP5-pSEC-tag-transfected 293T cells ...
Biology Products: